Loading...
Loading...
Browse all stories on DeepNewz
VisitRegion leading in adoption of saliva test by end of 2024?
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
Sales data and market analysis reports
New At-Home Saliva Test for Prostate Cancer Analyzing DNA Markers Could Save Thousands of Lives
May 31, 2024, 11:07 PM
Scientists have developed a new at-home saliva test for prostate cancer that promises to revolutionize detection and treatment. The test, which analyzes DNA markers in saliva to determine genetic risk, could save thousands of lives and significantly reduce healthcare costs. This advancement is particularly beneficial for individuals with limited, low-grade, slow-growing prostate cancer who wish to delay surgery or radiation due to concerns about side effects. The test, praised for its affordability and quick results, is expected to enable widespread screening, especially among middle-aged men, potentially turning the tide on prostate cancer. The development has been highlighted by the Daily Express and is based on a landmark study, showcasing the power of domestic diagnostics.
View original story
North America • 25%
Europe • 25%
Asia • 25%
Rest of the World • 25%
North America • 25%
Europe • 25%
Asia • 25%
Rest of the World • 25%
Asia • 25%
Europe • 25%
North America • 25%
Other regions • 25%
North America • 20%
Europe • 20%
Asia-Pacific • 20%
Latin America • 20%
Middle East & Africa • 20%
North America • 25%
Europe • 25%
Asia • 25%
Rest of the World • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
High in urban areas • 25%
High in rural areas • 25%
Uniform across regions • 25%
Low overall adoption • 25%
North America • 25%
Europe • 25%
Asia • 25%
Rest of the World • 25%
North America • 25%
Europe • 25%
Asia • 25%
Rest of the World • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Rest of the World • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia • 25%
Latin America • 25%
HealthGen • 25%
TestCo • 25%
BioMark • 25%
Other • 25%